Evolution of insulin resistance in coronary artery disease patients on four different pharmacological therapies

Gonzalo Piédrola, Enrique Novo, Joaquin Serrano-Gotarredona, Maria Luisa de Teresa, Rafael García-Robles

Summary
The objective of the study was to examine the evolution of insulin sensitivity in a group of patients with stable coronary artery disease receiving one of four different pharmacological therapies. Insulin sensitivity was evaluated using an insulin suppression test in 40 newly diagnosed patients with coronary artery disease and no previous history of metabolic disorders, who were not taking any medication which might affect insulin sensitivity. The insulin suppression test consisted of a constant infusion of glucose, insulin and somatostatin for 150 min; insulin resistance was estimated by determining the steady-state plasma glucose concentrations during the last 60 minutes of the test. The insulin sensitivity index was calculated by the formula: insulin sensitivity index = (glucose infusion rate/steady state plasma glucose concentrations) \times 10^3. A second insulin suppression test was performed after 6 months' therapy with either isosorbide mononitrate, atenolol, diltiazem or captopril in 30 of the 40 patients.

There were no differences between any of the groups before therapy was initiated. After 6 months, patients treated with captopril and, to a lesser extent, those treated with diltiazem showed statistically significantly decreased steady state plasma glucose concentrations and increased insulin sensitivity index compared to basal values. No statistically significant differences were found in the other two groups.

We conclude that captopril and, to a lesser extent, diltiazem improve insulin sensitivity in patients with stable coronary artery disease.

Keywords: insulin resistance; coronary artery disease; captopril; diltiazem

Three prospective studies have shown an independent association between hyperinsulinaemia and CAD in men with no known glucose intolerance. As hyperinsulinaemia can be considered a consequence of insulin resistance when beta cell function is conserved, these studies suggest that hyperinsulinaemia and insulin resistance might be risk factors for CAD. A few recent reports, including one of our own, support this hypothesis, demonstrating that CAD patients are truly insulin resistant, even when confounding risk factors are excluded.

Moreover, the Framingham Heart Study emphasized the greater morbidity and mortality due to coronary, cerebral and peripheral vascular disease in patients with arterial hypertension. As a result, courses of treatment were initiated to lower blood pressure in these patients, and consequently, reduce the risk of vascular disease; this was achieved in the case of cerebrovascular disease, however, no significant change was observed in morbidity and mortality resulting from CAD. This failure has been partly attributed to the possible effects of the drugs used to lower blood pressure on insulin sensitivity.

Since the presence of insulin resistance has been related to the subsequent development of CAD, and the effects of the drugs presently used in the treatment of CAD have yet to be established, the present study attempted to evaluate the effects of four different conventional therapies on the evolution of insulin-stimulated glucose uptake, in a group of patients with stable CAD at diagnosis.

Metabolic abnormalities related to underlying decreased insulin sensitivity

- hyperinsulinaemia
- arterial hypertension
- hyperglycaemia and glucose intolerance
- hypertriglyceridaemia
- decreased HDL-cholesterol
- hyperuricaemia
- decreased dehydroepiandrosterone sulfate
- obesity
Methods

PATIENTS
Forty newly diagnosed stable angina pectoris patients were included in the study. The diagnosis of CAD was established on the basis of a typical history of exertional chest pain, associated with electrocardiographic (ECG) changes during a treadmill exercise test (ST segment depression > 0.1 mV; n=34) and/or significant coronary stenosis on coronary angiography (n=15). None of the patients were taking any medication with potential effects on insulin sensitivity (beta-blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, alpha-antagonists), or for coronary heart disease (calcium channel blockers, nitrates), with the exception of acetylsalicylic acid. Patients were excluded if they had a previous history of glucose intolerance or hyper- tension, body mass index (BMI) > 30 kg/m², or previous history of glucose intolerance or hyper- acid. Patients were excluded if they had a pre- significant coronary stenosis on coronary angiography (n=15). None of the patients were taking any medication with potential effects on insulin sensitivity (beta-blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, alpha-antagonists), or for coronary heart disease (calcium channel blockers, nitrates), with the exception of acetylsalicylic acid. Patients were excluded if they had a previous history of glucose intolerance or hypertension, body mass index (BMI) > 30 kg/m², or fasting plasma glucose > 140 mg/dl. Subjects who had signs or symptoms of cardiac failure, renal failure, liver disease, or other chronic or intercurrent illness were also excluded from the study. The basal characteristics of these patients have been reported previously.8

The protocol was approved by the Ramón y Cajal Hospital Ethics Committee, and informed consent was obtained from all patients and controls.

EXPERIMENTAL DESIGN
To determine eligibility, medical history, physical examination (including systolic and diastolic blood pressure measured to the nearest 2 mmHg using a standard sphygmonanometer by a single, trained examiner), fasting serum biochemical data (glucose, creatinine, liver enzymes, uric acid, lipids and ions), and a 12-lead ECG and treadmill exercise test were performed on the first day.

Insulin sensitivity, as opposed to insulin resistance, was assessed using a modified version of the insulin suppression test (IST).12 13 This test involved the suppression of endogenous insulin secretion with a sustained infusion of somatostatin. Exogenous crystalline insulin was infused simultaneously, at a constant rate, to achieve a steady state plasma insulin (SSPI). The resultant steady state of plasma glucose (SSPG) in response to a constant glucose infusion was determined.

Patients were asked to return to the Endocrine-Metabolic testing room between 08.00 and 09.00 h, after a 12-h overnight fast; two indwelling intravenous lines were placed in both forearm veins and, after 15 to 30 minutes of acclimatisation, basal blood samples were obtained. A continuous infusion of glucose (6 mg/kg/min), insulin (0.77 mIU/kg/min) and somatostatin (125 µg in bolus, followed by a constant infusion of 350 µg/h) was performed for a total of 150 min. Blood samples were obtained at 30, 60, 90, 100, 110, 120, 130, 140, and 150 min, for measurement of plasma glucose and insulin concentrations. The mean of the last seven measurements was used to estimate the SSPI and SSPG achieved during the test. The insulin sensitivity index (ISI) was calculated by the formula:

\[
\text{ISI (dl/kg/min)} = \frac{\text{glucose infusion rate (mg/kg/min)}}{\text{SSPG (mg/dl)}} \times 10^3
\]

As the insulin and glucose infusion were the same in all subjects (on a kg basis), the SSPI would be similar in all of them but the resulting SSPG and ISI obtained depended on the individual’s disposal of plasma glucose, providing a measure which was directly proportional to the insulin sensitivity, and inversely proportional to the insulin resistance, of the individual patient. The test was performed on each patient before anti-ischaemic therapy was initiated; immediately afterwards, the 40 patients were randomly assigned to one of the following therapeutic groups, with 10 patients per group:

- nitrates: isosorbide mononitrate (40 mg/d)
- calcium antagonists: diltiazem (180 mg/d)
- beta-blockers: atenolol (50 mg/d)
- ACE inhibitors: isosorbide mononitrate (40 mg/d) + captopril (25 mg/d)

All patients also received 200 mg acetylsalicylic acid (ASA) daily.

After 6 months of anti-ischaemic therapy, patients were asked to return to the Endocrine-Metabolic testing room, where a second IST was performed.

ASSAYS
Plasma glucose was assayed by the glucose oxidase method (Beckman Glucose Analyzer, Beckman Instruments, Fullerton, CA, USA). A commercial radioimmunoassay was used for determination of serum insulin (Sorin Biomedica SpA, Saluggia, Italy). C-Peptide levels were measured by another commercial radioimmunoassay (Incstar Corporation, Stillwater, MN, USA). The mean intra- and interassay coefficients of variation, as reported by the manufacturer, were 7.6% and 8.9% for insulin and 6.2% and 14.8% for C-peptide, respectively.

STATISTICAL ANALYSIS
When studying the differences in SSPG, SSPI and ISI between groups prior to treatment, a one-way analysis of variance was performed. In SSPG, natural logarithm transformation was carried out because variances were unequal. The analysis of a nested design was used to study the differences between levels before and after therapy in each group, applying the Bonferroni correction for multiple comparisons when interaction was significant; three factors were present:

- therapy, with four levels (nitrates, calcium antagonists, beta-blockers, angiotensin converting enzyme inhibitors), a fixed effect factor
- SSPG, ISI and SSPI evolution, with two levels (basal and after therapy), a fixed effect factor
- persons, a random-effect factor nested in groups.

A difference of p<0.05 was considered significant. The results are expressed as mean ± SD in tables, and as mean ± SE in figures.
Results

Thirty of the 40 patients were re-evaluated after 6 months of treatment (eight in the calcium antagonists and ACE inhibitors groups and seven in the nitrates and beta-blockers groups). The remaining 10 no longer fulfilled the study requirement and were therefore excluded (three required more drugs during the follow-up period, three did not give a reason, two required by-pass surgery due to their CAD, one went abroad and one died). Thus, the following data only refer to the 30 patients who were re-evaluated.

There were no differences in the values obtained during the first IST (performed before therapy was initiated) in SSPG, ISI, SSPI, fasting plasma glucose, fasting plasma insulin, fasting plasma C peptide, age or BMI between the four groups studied (table).

The results of the second IST showed that SSPG values had decreased significantly during the 6-month follow-up period in patients treated with ACE inhibitors or with calcium antagonists (figure 1), whilst no differences were observed in the other groups (nitrates and beta-blockers). Similarly, ISI levels were significantly higher after treatment in the patients who received ACE inhibitors and, to a lesser extent, calcium antagonists, but no differences were observed in the other two groups (figure 2).

The SSPIs obtained during both ISTs were similar in all groups. No differences were found in fasting plasma glucose, fasting plasma insulin or fasting plasma C-peptide before and after therapy between any of the groups. There was no significant change in BMI during the study.

Discussion

Resistance to insulin-stimulated glucose uptake and hyperinsulinaemia have been related to the pathogenesis and development of several metabolic abnormalities, including non-insulin-dependent diabetes mellitus (NIDDM), hypertension, dyslipidaemia and obesity, which are well known risk factors for CAD. Following Reaven's definition of the metabolic syndrome X, numerous studies have attempted to clarify this complex web of disorders and their relationship with the subsequent development of atherosclerosis and, particularly, CAD. Patients with both microvascular angina and organic coronary stenosis have been shown to be insulin resistant, even when the characteristic risk factors are excluded.

Since these patients are insulin resistant, the effects of standard CAD treatments on insulin sensitivity may be an important factor, as any beneficial or harmful actions may influence the accompanying coronary morbidity and mortality. The metabolic effects of these drugs have been investigated extensively in arterial hypertension, but have yet to be...
studied in CAD; in general, ACE inhibitors have been reported to improve insulin-stimulated glucose uptake, both in NIDDM and in non-diabetic hypertensive patients, and to decrease fasting plasma glucose and glycated haemoglobin in diabetic hypertensive patients. However, the role of calcium antagonists in glucose metabolism has not been completely elucidated; reports range from alterations in insulin liberation in non-diabetic patients treated with nifedipine to both neutral and beneficial results found with diltiazem, with amelioration of hyperinsulinaemic resistance. Beta-blockers, both non-selective and beta-1 selective adrenergic antagonists, have been shown to worsen glucose tolerance and to decrease insulin sensitivity in hypertensive patients; these deleterious metabolic consequences seem to be related not only to a peripheral decrease in glucose oxidation but also to inhibition of insulin release by beta cells. No clear metabolic effects of nitrates have been reported to date. Stress is known to increase insulin resistance. Our patients were very probably under some stress during the first IST; the stress would probably have been much lower in the second IST as the test was no longer new to them; this would not alter the beneficial results found with captopril and diltiazem, since the statistical method evaluates the differences in evolution of the four groups studied and not the individual variation with respect to pretreatment values. However, it does emphasize the deterioration in SSPG and ISI throughout the evolution of the atenolol group (in contrast to the other three groups).

The technique used to quantify insulin sensitivity was the insulin suppression test, a simple and cost-effective alternative to the euglycaemic hyperinsulinaemic clamp (considered the gold standard method) for the measurement of insulin resistance, which has been used increasingly often in recent years.

17 18 The IST consists of a constant intravenous infusion of glucose and insulin, with the addition of epinephrine and propranolol to suppress endogenous insulin secretion, although this is actuated by somatostatin infusion. We have been using this method successfully in both dogs and humans, without major problems.

Our study shows the effects of four conventional courses of treatment for CAD on insulin sensitivity. Captopril produced a highly significant improvement in insulin sensitivity (p=0.0008). Some improvement was also seen on diltiazem (p=0.0340). Insulin sensitivity did not appear to worsen notably with the use of atenolol, although it should be borne in mind that only seven patients could be re-evaluated, and that this was the only group in which there was an apparent tendency towards worsening. Isosorbide mononitrate did not seem to have any effect on insulin sensitivity. These data seem to corroborate the reported effects of these drugs on insulin sensitivity in hypertensive patients, and support a possible beneficial role for captopril, and possibly diltiazem, in the treatment and secondary prevention of CAD.

For the reasons mentioned above, and since captopril and diltiazem seem to offer beneficial metabolic profiles in the long-term treatment of CAD, it would appear advisable to administer the first two drugs in preference to atenolol, at least in cases where there is no clear cardiovascular indication for the beta-blocker. However, it must be remembered that many factors, other than metabolic ones, intervene in the pathogenesis of CAD; therefore, these recommendations should be followed with great caution.

In conclusion, we have demonstrated that the use of captopril and, to a lesser extent, diltiazem by CAD patients is accompanied by an improvement in insulin sensitivity. Therefore, captopril and diltiazem might be regarded as a first choice therapy in the management of CAD, especially in the presence of associated metabolic anomalies.

This research was supported by Clinical Investigation Grant from the Hospital Ramón y Cajal, Madrid, Spain (GP) and Research Project Grant # 93/1 (BMS) from Plan Nacional de Fomento a la Investigación, Spain.

We are indebted to Mrs María Teresa Embid, Mrs Purificación Moyano and Mrs Anne J Macmichael for their technical assistance.
